Hemostemix Inc. (HEM.V)
CAD 0.1
(26.67%)
CAD 0.1
(26.67%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 313.76 Thousand CAD | -32.57% |
| 2022 | 465.34 Thousand CAD | -17.35% |
| 2021 | 563.04 Thousand CAD | -75.76% |
| 2020 | 2.32 Million CAD | 2127.73% |
| 2019 | 104.28 Thousand CAD | -93.73% |
| 2018 | 1.66 Million CAD | -68.65% |
| 2017 | 5.3 Million CAD | 2234.76% |
| 2016 | 227.11 Thousand CAD | -71.5% |
| 2015 | 796.8 Thousand CAD | -79.78% |
| 2014 | 3.94 Million CAD | 382.51% |
| 2013 | 816.84 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 243.77 Thousand CAD | 158.35% |
| 2024 Q1 | 94.36 Thousand CAD | -69.93% |
| 2023 FY | 313.76 Thousand CAD | -32.57% |
| 2023 Q2 | 305.11 Thousand CAD | -39.06% |
| 2023 Q1 | 500.7 Thousand CAD | 7.6% |
| 2023 Q4 | 313.76 Thousand CAD | -55.25% |
| 2023 Q3 | 701.14 Thousand CAD | 129.8% |
| 2022 Q1 | 1.34 Million CAD | 139.73% |
| 2022 FY | 465.34 Thousand CAD | -17.35% |
| 2022 Q2 | 821.99 Thousand CAD | -39.1% |
| 2022 Q3 | 1.17 Million CAD | 42.42% |
| 2022 Q4 | 465.34 Thousand CAD | -60.25% |
| 2021 Q3 | 2.38 Million CAD | -18.02% |
| 2021 Q1 | 925.96 Thousand CAD | -60.14% |
| 2021 Q2 | 2.91 Million CAD | 214.64% |
| 2021 FY | 563.04 Thousand CAD | -75.76% |
| 2021 Q4 | 563.04 Thousand CAD | -76.42% |
| 2020 Q2 | 609.8 Thousand CAD | 26.01% |
| 2020 Q3 | 253.41 Thousand CAD | -58.44% |
| 2020 Q4 | 2.32 Million CAD | 816.72% |
| 2020 Q1 | 483.93 Thousand CAD | 364.07% |
| 2020 FY | 2.32 Million CAD | 2127.73% |
| 2019 Q4 | 104.28 Thousand CAD | -63.29% |
| 2019 FY | 104.28 Thousand CAD | -93.73% |
| 2019 Q3 | 284.05 Thousand CAD | 177.63% |
| 2019 Q2 | 102.31 Thousand CAD | -85.39% |
| 2019 Q1 | 700.12 Thousand CAD | -57.88% |
| 2018 FY | 1.66 Million CAD | -68.65% |
| 2018 Q4 | 1.66 Million CAD | -39.45% |
| 2018 Q3 | 2.74 Million CAD | -30.42% |
| 2018 Q2 | 3.94 Million CAD | -21.22% |
| 2018 Q1 | 5 Million CAD | -5.55% |
| 2017 Q1 | 392.51 Thousand CAD | 72.83% |
| 2017 Q2 | 251.32 Thousand CAD | -35.97% |
| 2017 Q3 | 5.88 Million CAD | 2241.39% |
| 2017 Q4 | 5.3 Million CAD | -9.89% |
| 2017 FY | 5.3 Million CAD | 2234.76% |
| 2016 Q4 | 227.11 Thousand CAD | -42.28% |
| 2016 FY | 227.11 Thousand CAD | -71.5% |
| 2016 Q1 | 349.19 Thousand CAD | -56.18% |
| 2016 Q2 | 330.18 Thousand CAD | -5.44% |
| 2016 Q3 | 393.48 Thousand CAD | 19.17% |
| 2015 Q1 | 3.06 Million CAD | -22.2% |
| 2015 Q4 | 796.8 Thousand CAD | -34.01% |
| 2015 Q3 | 1.2 Million CAD | -45.8% |
| 2015 Q2 | 2.22 Million CAD | -27.34% |
| 2015 FY | 796.8 Thousand CAD | -79.78% |
| 2014 Q2 | 240.97 Thousand CAD | 11.57% |
| 2014 Q1 | 215.98 Thousand CAD | -8.75% |
| 2014 FY | 3.94 Million CAD | 382.51% |
| 2014 Q4 | 3.94 Million CAD | 2161.34% |
| 2014 Q3 | 174.29 Thousand CAD | -27.67% |
| 2013 FY | 816.84 Thousand CAD | 0.0% |
| 2013 Q2 | 277.34 Thousand CAD | -6.19% |
| 2013 Q3 | 254.16 Thousand CAD | -8.36% |
| 2013 Q4 | 236.68 Thousand CAD | -6.88% |
| 2013 Q1 | 295.63 Thousand CAD | 142.25% |
| 2012 Q4 | 122.03 Thousand CAD | -3.14% |
| 2012 Q3 | 126 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Arch Biopartners Inc. | 1.17 Million CAD | 73.209% |
| Covalon Technologies Ltd. | 24.9 Million CAD | 98.74% |
| Universal Ibogaine Inc. | 6.31 Million CAD | 95.033% |
| Kane Biotech Inc. | 5.68 Million CAD | 94.477% |
| MedMira Inc. | 3.65 Million CAD | 91.408% |
| Marvel Biosciences Corp. | 672.38 Thousand CAD | 53.336% |
| NervGen Pharma Corp. | 13.23 Million CAD | 97.629% |
| XORTX Therapeutics Inc. | 7.21 Million CAD | 95.648% |